Blood test predicts survival after surgery for early-stage lung cancer

AI Insight

The NeoCOAST-2 study investigated the relationship between circulating tumor DNA (ctDNA) clearance and clinical outcomes in patients with resectable lung cancer undergoing neoadjuvant treatment. The research demonstrates that monitoring ctDNA levels before surgery can serve as a biomarker for treatment response and predict patient outcomes. Patients who achieved ctDNA clearance showed improved survival rates compared to those with persistent detectable ctDNA.

Why it matters

This finding could enable clinicians to personalize treatment strategies for lung cancer patients by identifying those who respond well to neoadjuvant therapy versus those who may need alternative approaches. The use of ctDNA as a non-invasive liquid biopsy could also help optimize surgical timing and post-operative monitoring protocols.